BBP Performance — Virtus LifeSci Biotech Products ETF
Data updated: 2026-09-29
BBP returned +17.67% year to date and +52.32% over one year to Jul 2026. Annualised returns are +19.48% over 3 years and +13.16% over 5 years. The fund beat its Health Care Equity category average: $100 invested three years ago grew to $171, against $137 for the category, and to $152 over one year, against $137. Volatility over the past three years was 18.96% a year. In the 12 months to Jul 2026 the fund took in a net $56.3M, and assets reached $98.54M.
BBP Growth of $100
What $100 invested in Virtus LifeSci Biotech Products ETF grew to, compounded from monthly returns reported on SEC Form N-PORT, against the Health Care Equity category average over the same months.
| Period | BBP | Category average |
|---|---|---|
| 1 year (Aug 2025 – Jul 2026) | $152 | $137 |
| 3 years (Aug 2023 – Jul 2026) | $171 | $137 |
| 5 years (Aug 2021 – Jul 2026) | $186 | $121 |
| Since data start (Aug 2019 – Jul 2026) | $244 | $183 |
BBP Trailing Returns
Total returns to Jul 2026, from SEC N-PORT.
| Period | Total return |
|---|---|
| YTD | +17.67% |
| 1 year | +52.32% |
| 3 years (annualised) | +19.48% |
| 5 years (annualised) | +13.16% |
BBP Annual Returns
Calendar-year total returns of Virtus LifeSci Biotech Products ETF, compounded from monthly SEC N-PORT returns. Partial years show the months covered.
| Year | Total return |
|---|---|
| 2026 (Jan–Jul) | +17.67% |
| 2025 | +32.77% |
| 2024 | +3.62% |
| 2023 | +17.44% |
| 2022 | +0.97% |
| 2021 | −8.24% |
| 2020 | +22.19% |
| 2019 (Aug–Dec) | +13.49% |
BBP Monthly Returns
Monthly total returns as reported on SEC Form N-PORT.
| Year | Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | +2.3% | +4.3% | −1.9% | +1.4% | +2.2% | +11.4% | −2.7% | — | — | — | — | — |
| 2025 | +3.7% | −0.1% | −5.8% | +0.7% | −4.9% | +4.1% | +5.5% | +9.4% | +4.0% | +6.5% | +7.6% | −0.6% |
| 2024 | −1.0% | +3.8% | −4.8% | −6.7% | +7.1% | +3.9% | +6.8% | +2.2% | −1.9% | +0.4% | +3.8% | −8.5% |
| 2023 | +5.8% | −5.4% | −0.2% | +4.2% | +0.4% | +1.9% | +4.6% | −3.7% | −5.4% | −6.9% | +9.6% | +13.3% |
| 2022 | −11.6% | −2.6% | +3.1% | −10.9% | −2.2% | +9.3% | +2.9% | +11.1% | −4.1% | +3.1% | +7.5% | −1.7% |
| 2021 | +5.8% | −2.8% | −4.5% | +2.7% | −3.8% | +3.1% | −5.2% | +4.0% | −3.2% | +1.8% | −7.0% | +1.4% |
| 2020 | −4.8% | 0.0% | −9.7% | +16.8% | +5.8% | +2.4% | −5.2% | +4.6% | +1.3% | +1.2% | +7.2% | +3.1% |
| 2019 | — | — | — | — | — | — | — | −3.1% | −3.5% | +5.5% | +16.5% | −1.2% |
BBP Risk
Risk measures from monthly returns over Aug 2023 – Jul 2026.
- 3-year volatility (annualised): 18.96%
- 3-year Sharpe ratio: 0.79 (vs 4.5% risk-free rate)
- Best month: +13.29% (Dec 2023)
- Worst month: −8.52% (Dec 2024)
BBP Fund Flows
Monthly money in and out of Virtus LifeSci Biotech Products ETF, from SEC Form N-PORT.
- 12-month net flow: $56.3M
- 12-month gross sales (incl. reinvestments): $69.5M
- Sales ÷ redemptions: 5.25×
| Month | Sales | Redemptions | Net flow |
|---|---|---|---|
| Jul 2026 | $14.9M | $0 | $14.9M |
| Jun 2026 | $13.1M | $13.2M | −$162K |
| May 2026 | $17.4M | $0 | $17.4M |
| Apr 2026 | $4.3M | $0 | $4.3M |
| Mar 2026 | $4.1M | $0 | $4.1M |
| Feb 2026 | $4.1M | $0 | $4.1M |
| Jan 2026 | $0 | $0 | $0 |
| Dec 2025 | $11.7M | $0 | $11.7M |
| Nov 2025 | $0 | $0 | $0 |
| Oct 2025 | $0 | $0 | $0 |
| Sep 2025 | $0 | $0 | $0 |
| Aug 2025 | $0 | $0 | $0 |
BBP Assets Under Management
Net assets of Virtus LifeSci Biotech Products ETF by report date, from SEC N-PORT filings.
| Report date | Net assets |
|---|---|
| 2026-07-31 | $98.54M |
| 2026-04-30 | $59.29M |
| 2026-01-30 | $44.87M |
| 2025-10-31 | $29.85M |
| 2025-07-31 | $24.65M |
| 2025-04-30 | $23.61M |
| 2025-01-31 | $21.80M |
| 2024-10-31 | $22.14M |
| 2024-07-31 | $22.00M |
| 2024-04-30 | $18.51M |
| 2024-01-31 | $17.22M |
| 2023-10-31 | $14.00M |
For information only. Not investment advice: figures are as reported in SEC filings and may contain errors or be out of date. Past performance does not guarantee future results.